CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 40 enrolled
Drug / intervention
Progesterone 100 MGdrug
Likely dose
Progesterone 100 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04365127
NCT04365127Phase 1Completed
CompareCT.gov

A Single Center, Randomized, Controlled Trial of the Safety and Efficacy of Progesterone for the Treatment of COVID-19 in Hospitalized Men

Sara Ghandehari·interventional·Posted Apr 28, 2020·Updated Jan 27, 2021

In Brief

A Phase 1 clinical trial evaluating Progesterone 100 MG for COVID-19 and Sars-CoV2. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to assess safety and efficacy of progesterone for treatment of COVID-19 in hospitalized men.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Sars-CoV2
CountriesUnited States
CollaboratorsIBSA Institut Biochimique SA

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedApr 28, 2020
Enrollment StartApr 27, 2020
Primary CompletionAug 20, 2020
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.2 years ago

Interventions

Progesterone 100 MGdrug

Subcutaneous administration twice daily